Moran Wealth Management 13F: New $2.3M Stake in NUTX

Moran Wealth Management opened a new stake in Nutex Health Inc. NUTX, acquiring 10,994 shares worth about $2.33 million. According to a Form 13F filing with the SEC on October 22, 2026, the fund initiated the holding during the period. The stock closed at $206.09 on the filing date.

NUTX Nutex Health Inc.

$206.09 ▲ +39.07% year to date

1M 3M YTD

Daily close · Oct 22, 2026

What Changed in Moran Wealth Management's Nutex Health Position

Moran Wealth Management stepped into Nutex Health Inc. with 10,994 shares. The newly established position carried a reported value of $2,326,990 based on the filing details. Because this is a brand-new stake, the fund did not previously hold shares in the healthcare provider.

Other Institutional Activity in Nutex Health

Other major funds also adjusted positions in the medical facility operator ahead of the filing. Pertento Partners LLP grew its holdings by 77,338 shares, ending with 451,310 shares worth about $93.01 million. American Century Companies Inc added 33,957 shares, lifting its stake to 237,414 shares valued at about $48.93 million. Shaw D.E. & Co., Inc. doubled its holdings by adding 48,727 shares, finishing with 97,454 shares worth roughly $20.08 million. Winmill & Co. Inc kept its position steady at 65,350 shares valued at about $13.47 million. Focus Partners Wealth opened a new position by adding 30,440 shares, bringing its total to 60,881 shares worth about $12.55 million.

Nutex Health Inc. Stock Up 4.3%

Nutex Health Inc. shares recently traded at $206.09 as of October 23, 2026, remaining right around the $206.09 close seen on October 22. The stock trades above its 50-day moving average of $200.84 and sits well above its 200-day moving average of $149.53. Shares range from a 52-week low of $83.99 up to a high of $226.16.

Recent Earnings

Nutex Health Inc. reported trailing-twelve-month revenue of $846.72 million alongside earnings of $25.24 per share. The company posted a net profit margin of 21.2% and a return on equity of 64.6%. Investors look toward the upcoming earnings release on November 5, 2026, for fresh operational updates.

Insider Buying and Selling at Nutex Health Inc.

Company insiders have transacted in the stock across several dates. Director Kelvin Spears bought 10 shares on March 17, 2026, at $94.46 per share for $945.00. President Warren Hosseinion bought 252 shares on March 19, 2026, at $94.07 per share for $23,706.00. Director Frank E Jaumot bought 150 shares on March 20, 2026, at $93.56 per share for $14,033.00. Later, Director Scott J Saunders sold 203 shares on September 18, 2026, at $214.25 per share for a total value of $43,492.75.

Analysts Set New Price Targets

Wall Street firms have updated their outlooks on the stock across several dates. On June 26, 2026, B. Riley Securities initiated coverage with a buy rating and a $290.00 price target. Lake Street maintained a buy rating on August 11, 2026, raising its target to $310.00 from $235.00. B. Riley Securities maintained a buy rating on September 4, 2026, lifting its target to $325.00 from $290.00. Freedom Capital Markets maintained a buy rating on September 25, 2026, raising its target to $306.00 from $280.00. Across five analyst opinions, the stock holds a consensus buy rating with a mean price target of $288.20.

About Nutex Health

Nutex Health Inc. operates healthcare facilities in the United States through hospital, population health management, and real estate segments. The company develops and runs a network of micro-hospitals, specialty hospitals, and outpatient departments that deliver emergency care, inpatient services, and behavioral health programs.

Bottom Line

Market participants continue monitoring institutional allocation trends alongside upcoming corporate milestones. Nutex Health Inc. is scheduled to release its next financial results on November 5, 2026.